ClinicalTrials.gg
RecruitingNCT07468136Updated Jun 24, 2026

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

A Phase 1/2 interventional study of Biospecimen Collection and Eflornithine in Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 and Astrocytoma, IDH-Mutant, Grade 4, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Mayo Clinic · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 339 studies in Oligodendroglioma with a site in United States — 19 open to participants now, 35 under way, 4 of them phase 3. Oligodendroglioma · United States.

Planned enrollment
123rd of 273
33 · median 30
Started
2026
with 5 others
Phase 1/2
40 of 339
3 open now
Primary completion
2030-10
later than 30 of 34 live
Registered
336th of 339
by date

Among the 339 studies in Oligodendroglioma with a site in United States, this one is the 123rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 in phase 1/2, reaches primary completion later than 30 of the 34 other live ones, and was the 336th registered.

Oligodendroglioma

414 studies on the registry are indexed under Oligodendroglioma; 33 are open to participants now.

Browse Oligodendroglioma studies →

Open to participants now

19 of the 339 studies in Oligodendroglioma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Oligodendroglioma studies recruiting now, 16 (62%) set no upper age limit and 7 (27%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 339 studies in Oligodendroglioma with a site in United States, or all of them as a file.
02

Study summary

This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitors. It works by blocking the action of a substance that signals tumor cells to multiply. This helps stop or slow the spread of tumor cells. Giving retifanlimab with or without DFMO mat be safe, tolerable and/or effective in treating patients with progressive high grade glioma.

03

Conditions studied

  • Anaplastic Oligodendroglioma
  • Astrocytoma, IDH-Mutant, Grade 3
  • Astrocytoma, IDH-Mutant, Grade 4
  • Diffuse Astrocytoma
  • Glioblastoma, IDH-Wildtype
  • Malignant Glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of high-grade glioma, including any of the following:

    • Glioblastoma, IDH-wild type (WT)
    • Grade 3 or 4 IDH1/2 mutant astrocytoma or
    • Grade 3 oligodendroglioma
    • Any prior grade 2 astrocytoma or oligodendroglioma that is suspected to have recurred at a higher grade
    • Other high-grade glioma
  • Plan for surgical resection as part of routine clinical care
  • Radiographic disease progression, with or without tissue confirmation
  • (ECOG) performance status (PS) of 0, 1 or 2 and Performance Status (KPS) ≥ 60

    • NOTE: PS must be assessed (again) within 7 days prior to first dose of study drug
  • ≥ 9.0 g/dL (obtained ≤ 15 days prior to registration)
  • (ANC) ≥ 1500/mm\^3 (obtained ≤ 15 days prior to registration)
  • count ≥ 100,000/mm\^3 (obtained ≤ 15 days prior to registration)
  • Total ≤ 1.5 x (ULN) (obtained ≤ 15 days prior to registration)
  • (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement) (obtained ≤ 15 days prior to registration)
  • Calculated ≥ 45 ml/min using the Cockcroft-Gault formula (obtained ≤ 15 days prior to registration)
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of only
  • Provide written for the current study
  • Willing to provide consent for the Neuro-oncology biorepository (IRB 12-003458) for archiving of tissue, cerebrospinal fluid (CSF), and/or blood samples
  • Ability to complete forms by themselves or with assistance
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Exclusion criteria

Exclusion Criteria:

  • Any of the following because this study involves an agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of or able to father a child who are unwilling to employ adequate
  • Uncontrolled intercurrent illness that by the judgement of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the regimens including, but not limited to:

    • ongoing or active infection (e.g., pneumonia, sepsis, etc.) requiring systemic therapy
    • current diagnosis or previous history of immune-related (non-infectious) pneumonitis or interstitial lung disease that requires or required
    • active disease that required systemic treatment other than replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids) ≤ 2 years prior to registration
    • symptomatic congestive heart failure
    • unstable angina pectoris
    • psychiatric illness/social situations that would limit compliance with study requirements (e.g., drug addiction)
    • concurrent active (defined as hepatitis B surface antigen [HBsAg] positive and/or detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA]) and virus (defined as anti-hepatitis C virus [HCV] antibody [Ab] positive and detectable HCV ribonucleic acid [RNA]) infection

EXCEPTIONS:

  • Patients with evidence of hepatitis B virus (HBV) infection (HBsAg positive) must have completed at least 4 weeks of HBV antiviral therapy, and the HBV viral load must be undetectable at the time of registration
  • Patients with a history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load. Patients must have completed curative anti-viral treatment ≥ 4 weeks prior to registration.

    • NOTE: Patients without symptoms or prior history do not require testing prior to registration

      • Co-morbid systemic illnesses or other severe concurrent disease that would make the patient inappropriate for entry into the study or interfere with proper assessment of safety and toxicity
      • History of myocardial infarction ≤ 6 months prior to registration or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
      • Active autoimmune disease that has required systemic treatment (other than replacement therapy) ≤ 1 year prior to registration
      • History of stem cell transplant
      • Receiving any other investigational agent with therapeutic intent
      • Participants who are unable to swallow the DFMO solution or who are at risk for impaired absorption of oral medication.
  • NOTE: This restriction includes, but is not limited to, vomiting, gastric resection/bypass, and duodenal/jejunal resection

    • Patients with known or allergy to DFMO or retifanlimab
    • to MRI or administration of gadolinium
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Group A (retifanlimab and DFMO then surgery)

    Patients receive retifanlimab IV, over 30 minutes on day 1 of cycle 1 and DFMO PO Q8H on days 1-14 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection surgery. Patients then receive retifanlimab IV, over 30 minutes, on day 1 of each cycle and DFMO PO Q8H on days 1-14 of each cycle. Cycles repeat every 28 days for 16 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and blood sample collection throughout the study and may optionally undergo CSF fluid collection with or without lumbar puncture.

    Procedure: Biospecimen Collection · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Biological: Retifanlimab · Procedure: Tumor Resection

  • Experimental
    Group B1 (retifanlimab only then surgery)

    Patients receive retifanlimab IV, over 30 minutes, on day 1 of cycle 1. Patients then undergo standard of care resection surgery. Patients then receive retifanlimab IV, over 30 minutes, on day 1 of each cycle and DFMO PO Q8H on days 1-14 of each cycle. Cycles repeat every 28 days for 16 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and blood sample collection throughout the study and may optionally undergo cerebrospinal fluid collection with or without lumbar puncture.

    Procedure: Biospecimen Collection · Drug: Eflornithine · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Procedure: Tumor Resection

  • Experimental
    Group B2 (retifanlimab and DFMO then surgery)

    Patients receive retifanlimab IV, over 30 minutes on day 1 of cycle 1 and DFMO PO Q8H on days 1-14 of cycle 1, in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection surgery. Patients then receive retifanlimab IV, over 30 minutes, on day 1 of each cycle and DFMO PO Q8H on days 1-14 of each cycle. Cycles repeat every 28 days for 16 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and blood sample collection throughout the study and may optionally undergo cerebrospinal fluid collection with or without lumbar puncture.

    Procedure: Biospecimen Collection · Drug: Eflornithine · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Biological: Retifanlimab · Procedure: Tumor Resection

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood and CSF collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • Given PO

    Also known as: Alpha-Difluoromethylornithine, DFMO, Difluoromethylornithine, Difluromethylornithine

  • ProcedureLumbar Puncture

    Undergo lumbar puncture

    Also known as: LP, Spinal Tap

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • BiologicalRetifanlimab

    Given IV

    Also known as: INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz

  • ProcedureTumor Resection

    Undergo resection surgery

06

What researchers measure

Primary outcomes

  1. Best tolerable dose level of Difluoromethylornithine (DFMO, or eflornithine) (phase I)

    Will use a modified Bayesian Optimal Interval phase I/II (BOIN12) trial design to identify a dose level that is tolerable and has sufficient/optimal pharmacodynamic effects \[e.g., maximum tolerated dose (MTD)\]. Will evaluate toxicity up front to determine dose levels that have acceptable tolerability. Both dose limiting toxicity and pharmacodynamic activity will be used to identify the best dose to bring forward for the phase IIa portion.

    Time frame: Up to 5 years

  2. Change in T cell/myeloid cell ratio (phase IIa)

    Will use a log2 transformation of this percentage measure. Will summarize this within each of the treatment arms, and will compare these measures between arms using a two-sample t-test or a nonparametric Wilcoxon rank sum test if not sufficiently normally distributed.

    Time frame: From baseline up to 5 years

Secondary outcomes

  1. T cell/myeloid cell ratio

    Will use a two-sample t-test or the nonparametric Wilcoxon rank sum test to evaluate whether the combination of eflornithine (DFMO) and retifanlimab increases the average increase in the T cell/myeloid cell ratio versus with retifanlimab alone.

    Time frame: From baseline up to 5 years

  2. Myeloid cell abundance

    Will use a two-sample t-test or the nonparametric Wilcoxon rank sum test to evaluate if the combination of DFMO and retifanlimab increases the average increase in the T cell/myeloid cell ratio versus with retifanlimab alone.

    Time frame: Up to 5 years

  3. Extracellular cytokines/ chemokines

    Will evaluate concentrations of pro-inflammatory cytokines/chemokines, CSCL9 and CCL5 in tissue and in cerebrospinal fluid (CSF), and how these correspond or correlate to each other.

    Time frame: Up to 5 years

  4. Incidence of adverse events (AE)

    Assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number, type, and grade of adverse events will be summarized for each treatment arm.

    Time frame: Up to 5 years

  5. Progression free survival (PFS)

    Defined as the time from randomization to the time of documented progression and/or death due to any cause. Will be evaluated based on the Response Assessment in Neuro-Oncology criteria.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2030, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 12, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Oct 25, 2030
CompletionEst.
Oct 25, 2030
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07468136
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Jun 23, 2026
Primary completion
Oct 25, 2030 (estimated)
Completion
Oct 25, 2030 (estimated)
Last update
Jun 24, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Terence C. Burns, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflornithine · Retifanlimab

Start the discussion